Approved and Investigational Uses of Modafinil

  title={Approved and Investigational Uses of Modafinil},
  author={Raminder Kumar},
Modafinil is a wake-promoting agent that is pharmacologically different from other stimulants. It has been investigated in healthy volunteers, and in individuals with clinical disorders associated with excessive sleepiness, fatigue, impaired cognition and other symptoms. This review examines the use of modafinil in clinical practice based on the results of randomized, double-blind, placebo-controlled clinical trials available in the English language in the MEDLINE database. In sleep-deprived… 
Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review
Safety and Efficacy of Armodafinil in the Treatment of Excessive Sleepiness
Current evidence suggests that armodafinil significantly improves wakefulness in patients with excessive sleepiness in studies up to 12 weeks, and should be considered safe for use and monitored for adverse effects, particularly cardiovascular complications.
Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?
Clinical and preclinical research on MOD and its R-enantiomer, R-MOD, are highlighted and reported on the effects of MOD on psychostimulant-induced appearance of several symptoms that could intensify the severity of the disease, besides the potential therapeutic effects ofMOD on PSUD.
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects
Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine, and its psychotropic and cognitive effects are also attractive in several other pathologies and conditions that affect sleep structure, induce fatigue and lethargy, and impair cognitive abilities.
Wake-Promoting Pharmacotherapy for Psychiatric Disorders
The present review is aimed to provide an updated overview of the aforementioned compounds as well as investigational drugs in the field, in terms of mechanism of action, indications and use in clinical practice.
Modafinil Dependence: A Case with Attention-Deficit/Hyperactivity Disorder
It was realized that the patient, himself increased doses of Modafinil incrementally, in order to keep its effects on attention symptoms at the same level, and it has to be kept in mind that ADHD patients can develop ModafInil addiction.
Modafinil May Alleviate Poststroke Fatigue: A Randomized, Placebo-Controlled, Double-Blinded Trial
This is the first placebo-controlled trial to investigate treatment of poststroke fatigue with the wakefulness promoting drug modafinil and there were no significant differences between the 2 groups with regard to the primary end point.
Diretrizes brasileiras para o tratamento da narcolepsia Brazilian guidelines for the treatment of narcolepsy
This manuscript contains the conclusion of the consensus meeting of the Brazilian Sleep Association with Brazilian sleep specialists on the treatment of narcolepsy based on the review of medical


A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.
These data suggest that adjunctive modafinil at doses of 100-200 mg a day may improve depressive symptoms in patients with bipolar disorder.
Effects of modafinil on cognitive and meta‐cognitive performance
The generality of modafinil‐induced overconfidence is investigated and the need for continued research on the many complex interactions involving fatigue states, occasional versus long‐term stimulant use, and subjective assessments of fatigue and cognitive performance is highlighted.
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy
  • Fry
  • Psychology, Medicine
    Annals of neurology
  • 1998
Modafinil demonstrated an excellent safety profile for up to 40 weeks of open‐label treatment and efficacy was maintained, suggesting that tolerance will not develop with long‐term use.
Modafinil: A Review of Neurochemical Actions and Effects on Cognition
Overall, modafinil is an excellent candidate agent for remediation of cognitive dysfunction in neuropsychiatric disorders and shows initial promise for a variety of off-label indications in psychiatry.
A Randomized, Double-Blind, Crossover Trial of Modafinil on Mood
The results suggest that modafinil may have general mood-elevating effects accompanied by increased negative affect (anxiety) and may have implications for clinical practice, in particular for the adjunctive use of modaf in treatment-resistant depression.
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy
Modafinil is an effective treatment for excessive daytime sleepiness in narcolepsy and shows continued efficacy with up to 9 weeks of daily use and has an excellent safety profile and is very well tolerated.
Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome
Modafinil had mixed effects in two cognitive tasks and no effects were observed on the performance of other psychometric tests or on self-ratings of fatigue, quality of life or mood, but this may have been due to insufficient statistical power.
Modafinil affects mood, but not cognitive function, in healthy young volunteers
Modafinil is a selective wakefulness‐promoting agent with beneficial effects in narcolepsy and conditions of sleep deprivation and further changes in mood were revealed after the stress of cognitive testing, with the 100 mg group showing greater increases in the ‘psychological anxiety’ and the ’aggressive mood’ factors.
Modafinil: a double-blind multicentric study.
An overall benefit was noted by physicians as well as by patients, and MWT disclosed a positive effect of modafinil on excessive daytime sleepiness.